Two large independent studies raise further concern over increased risk of serious cardiac valve disease in patients treated for Parkinson's disease with ergoline dopamine agonists, pergolide and cabergoline.Sources:
Schade R, et al. Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation. N Engl J Med. 2007;356:29-38. Zanettini R. et al. Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease. N Engl J Med. 2007;356:39-46.